Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin With or Without Autologous Stem Cell Transplantation for the Treatment Relapsed or Refractory Multiple Myeloma or Newly Diagnosed, High Risk Multiple Myeloma

Inclusion Criteria

• Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information signed by the subject or his/her legally authorized representative. * NOTE: HIPAA authorization may be included in the informed consent or obtained separately
• Age ≥ 18 years at the time of consent. Because no dosing or adverse event data are currently available on the use of belantamab mafodotin as a single agent or in combination with KRd in subjects < 18 years of age, children are excluded from this study
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
• Absolute neutrophil count (ANC) ≥ 1.0 x 10^3/mm^3 * Note: no filgrastim or its equivalent may be given within 7 days of screening labs; no pegfilgrastim or its equivalent may be given within 14 days of screening labs
• Platelet Count ≥ 100 x 10^3/mm^3 * Note: no platelet transfusions may be given within 7 days of screening labs * Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin
• Hemoglobin (Hgb) ≥ 8 g/dL * Note: transfusion of packed red blood cells (PRBCs) to meet eligibility is allowed * Without growth factor support, blood transfusion, or platelet stimulating agents for the past 14 days, excluding erythropoietin
• Creatinine clearance ≥ 30 mL/min as measured by a 24-hour urine collection or estimated by the Cockcroft - Gault formula
• Albumin/creatinine ratio (from spot urine) ≤ 500 mg/g (56 mg/mmol)
• Total and fractionated bilirubin: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); except in subjects with congenital bilirubinemia, such as Gilbert syndrome (in which case a direct bilirubin ≤ 1.5 × ULN is required) (isolated bilirubin ≥ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%)
• Aspartate aminotransferase (AST) ≤ 2.5 × ULN
• Alanine aminotransferase (ALT) ≤ 2.5 × ULN
• Adequate cardiac function as defined by a > 40% left ventricular ejection fraction (LVEF) by ECHO, cardiac MRI or MUGA * Note for subjects in phase II: if a cycle of pre-study induction therapy containing a principal investigator (PI) or anthracycline was administered, assessment of the LVEF must be repeated
• For those with symptomatic pulmonary disease with grade 2 or higher symptoms (e.g. chronic obstructive pulmonary disease [COPD], asthma) or other signs / symptoms of pulmonary disease, adequate pulmonary function as defined by a forced expiratory volume in 1 second (FEV1) ≥ 50% of predicted and diffuse lung capacity for carbon monoxide (DLCO)/alveolar volume (VA) ≥ 50% of predicted
• Females of childbearing potential (FCBP) must have two negative serum pregnancy tests during screening: the first within 10-14 days prior to first dose of study treatment and the second within 24 hours prior to first dose of study treatment. * NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), are amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation; or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause)
• FCBP must be willing to use 2 effective contraceptive methods (at least one that is highly effective) or abstinence starting from the time of informed consent, while on belantamab mafodotin and lenalidomide. If either drug is discontinued, 2 effective forms of contraception should be continued until at least 4 weeks after the last dose of lenalidomide, and 1 form of effective contraception should be continued until 4 months post last dose of belantamab mafodotin. FCBP should use effective contraception or abstinence from consent until 30 days after last treatment with carfilzomib, and males with a partner of childbearing potential must use effective contraception or abstinence for at least 90 days post last dose of carfilzomib. Contraceptive methods with low user dependency are preferable but not required. * Contraceptives Allowed During the Study (Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for those participating in clinical studies): ** Highly Effective Methods that Have Low User Dependency: (Failure rate of < 1% per year when used consistently and correctly. Typical use failure rates differ from those when used consistently and correctly) *** Implantable progestogen-only hormone contraception associated with inhibition of ovulation (Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with Clinical Trial Facilitation Group guidelines, acceptable contraceptive methods are limited to those which inhibit ovulation as the primary mode of action) *** Intrauterine device (IUD) *** Intrauterine hormone-releasing system (IUS) (Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with Clinical Trial Facilitation Group guidelines, acceptable contraceptive methods are limited to those which inhibit ovulation as the primary mode of action) *** Bilateral tubal occlusion *** Vasectomized partner Note: Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. Spermatogenesis cycle is approximately 90 days ** Highly Effective Methods that are User Dependent (Failure rate of <1% per year when used consistently and correctly. Typical use failure rates differ from those when used consistently and correctly): *** Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with Clinical Trial Facilitation Group guidelines, acceptable contraceptive methods are limited to those which inhibit ovulation as the primary mode of action) **** oral **** intravaginal **** transdermal **** injectable *** Progestogen-only hormone contraception associated with inhibition of ovulation (Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with Clinical Trial Facilitation Group guidelines, acceptable contraceptive methods are limited to those which inhibit ovulation as the primary mode of action) **** oral **** injectable *** Sexual abstinence Note: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant Note: Periodic abstinence (calendar, sympto-thermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception for this study. Male condom and female condom should not be used together (due to risk of failure with friction)
• Male subjects must agree to the following from the first dose of study treatment until 6 months after the last dose of belantamab mafodotin, to allow for clearance of altered sperm: * Refrain from donating sperm PLUS either: * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR * Must agree to use effective contraception/barrier as detailed below: Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner of reproductive potential to use an additional highly effective contraceptive method with a failure rate of < 1% per year (including pregnant females)
• FCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction during the intervention period and for at least 4 months after the last dose of study intervention belantamab mafodotin, at least 30 days after the last dose of carfilzomib, and at least 4 weeks after the last dose of lenalidomide
• As determined by the enrolling physician, ability of the subject to understand and adhere with study procedures for the entire length of the study
• Ability to swallow oral medications
• Willing to refrain from using contact lenses while participating in this study
• PHASE I: Subjects with relapsed or relapsed/refractory multiple myeloma (MM) who have had at least 1 line of prior therapy. NOTES: * Refractory is defined as ˂ 25% reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment. * A line of therapy is defined as one or more cycles of a planned treatment program. This may consist of one or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse, or toxicity. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease
• PHASE I: Subjects must have measurable disease, as defined by at least one of the following: * Serum monoclonal protein level ≥ 0.5 g/dL * 24-hour urinary M-protein ≥ 200 mg * Involved free light chain level ≥ 10 mg/dL, along with an abnormal free light chain ratio (defined as < 0.26 or > 1.65)
• PHASE I: Subject must have not progressed on full dose lenalidomide previously (25 mg on days 1- 21 of a 28-day cycle or its dosing equivalent based on renal function at the time of progression)
• PHASE I: Prior to enrollment: * There should be a washout period of ≥ 14 days from any prior chemotherapy AND * The subject must have adequate recovery from toxicity of prior chemotherapy as defined by the following: ** Hematologic lab results within parameters ** Non-hematologic toxicity resolved to grade 1 or baseline with the following exceptions: *** Subjects who have started a course of antibiotic therapy for infection and symptoms have improved to baseline or grade 1, but remain on antibiotic therapy are eligible *** Subjects with ≤ grade 2 fatigue are eligible *** Subjects with ≤ grade 2 hyperglycemia are eligible, even if pharmacologic treatment was required *** Subjects with ≤ grade 2 electrolyte abnormalities are eligible, even if pharmacologic treatment was required *** Subjects with ≤ grade 2 nausea, constipation or diarrhea are eligible, even if pharmacologic treatment was required *** Subjects with < grade 2 peripheral neuropathy
• PHASE II: Active, newly diagnosed multiple myeloma with hypercalcemia, renal insufficiency, anemia, bone lesions (CRAB) features or a myeloma defining event per the IMWG 2014 criteria * Note: It is acceptable to include subjects who have had one cycle of emergent treatment for multiple myeloma
• PHASE II: High-risk disease, as defined by at least one of the following: * Del(1p) * Gain of 1q21 (≥ 3 copies) * Monosomy 13 or del(13q) by conventional karyotype * High risk IgH translocation [t(4;14), t(14;16) or t(14;20)] * del(17p)
• PHASE II: Measurable disease by 1 or more of the following: * Serum monoclonal protein level ≥ 0.5 g/dL * 24-hour urinary M-protein ≥ 200 mg * Involved free light chain level ≥ 10 mg/dL (100 mg/L), along with an abnormal free light chain ratio (defined as < 0.26 or > 1.65). * Note: for subjects who have received a prior cycle of non-protocol therapy, measurable disease will be based on the serum and urine monoclonal protein and serum free light chain levels prior to the cycle of non-protocol therapy
• PHASE II: No more than one prior cycle of non-protocol therapy will be allowed, recognizing that high-risk multiple myeloma subjects frequently require immediate therapy at initial diagnosis even before risk assessment is complete. For those subjects who receive a cycle of non-protocol induction therapy: * There should be a washout period of ≥ 14 days from the last dose of pre-study therapy AND * The subject must have adequate recovery from toxicity of pre-study therapy as defined by the following: ** Hematologic lab results within parameters ** Non-hematologic toxicity resolved to grade 1 or baseline with the following exceptions: *** Subjects who have started a course of antibiotic therapy for infection and symptoms have improved to baseline or grade 1, but remain on antibiotic therapy are eligible *** Subjects with ≤ grade 2 fatigue are eligible *** Subjects with ≤ grade 2 hyperglycemia are eligible, even if pharmacologic treatment was required *** Subjects with ≤ grade 2 electrolyte abnormalities are eligible, even if pharmacologic treatment was required *** Subjects with ≤ grade 2 nausea, constipation or diarrhea are eligible, even if pharmacologic treatment was required *** Subjects with < grade 2 peripheral neuropathy

Exclusion Criteria

• Active infection requiring systemic therapy * NOTE: at the discretion of the treating investigator, subjects who have started antibiotic therapy for subjects who had symptoms present, symptoms must have improved to baseline or grade 1 in severity may start treatment prior to completion of their course of antibiotic therapy
• Pregnant or breastfeeding * NOTE: breast milk cannot be stored for future use while the mother is being treated on study
• Subjects cannot have other prior or concomitant malignancies except for: * Curatively treated non-melanoma skin cancer * Other cancer for which the subject has been medically stable for at least 2 years and/or, in the opinion of the site principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy
• Active central nervous system (CNS) involvement
• Concomitant AL amyloidosis or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome
• Plasma cell leukemia
• Treatment with any investigational drug within 14 days or five half-lives, whichever is shorter, prior to first dose of study treatment
• Medical, psychiatric, or other condition/disorder (including lab abnormalities) which, in the opinion of the treating physician, would make this protocol treatment unreasonably hazardous for the subject, or could interfere with obtaining informed consent or compliance to the study procedures
• Significant cardiac disease, including any of the following: * ≥ Class 3 New York Heart Association (NYHA) congestive heart failure * Electrocardiogram (ECG) evidence of acute ischemia * Unstable angina * Myocardial infarction, coronary angioplasty, stenting, or bypass grafting within three months prior to day 1 of treatment * Clinically significant uncontrolled and/or untreated arrhythmias or conduction block, including clinically significant ECG abnormalities such as 2nd degree Mobitz Type ll or 3rd degree atrioventricular (AV)block. However, premature atrial contractions (PACs), premature ventricular contractions (PVCs), rate controlled atrial fibrillation, sinus arrhythmia, asymptomatic sinus bradycardia or sinus tachycardia and 1st degree heart block are not considered clinically significant * ≥ grade 2 Fridericia's corrected QT interval (QTcF) prolongation (i.e. > 480 msec) ** Note: Prior to study entry, any ECG abnormality at screening not felt to put the subject at risk must be documented by the investigator as not medically significant
• Uncontrolled hypertension, defined as a systolic blood pressure of ≥ 160 mmHg or a diastolic blood pressure of ≥ 90 mmHg
• Grade ≥ 2 peripheral neuropathy
• Psychiatric illness/social situation that would limit compliance with study requirements as determined by the investigator
• Known immediate or delayed hypersensitivity or allergic reaction to any components of, or related to, protocol therapy (e.g. during exposure to carfilzomib, lenalidomide or dexamethasone as part of a pre-study cycle of therapy)
• History of erythema multiforme to lenalidomide or other immunomodulatory imide drug (IMID)
• Discontinuation of prior carfilzomib, lenalidomide or dexamethasone due to treatment toxicity
• Major surgery within 4 weeks prior to day 1 of treatment
• Radiation within 14 days prior to day 1 of treatment. Note: palliative radiation (XRT) to < 5% of the total marrow volume as assessed by the treating investigator is allowed within 14 days prior to day 1 of treatment
• Current corneal epithelial disease except mild changes in corneal epithelium
• Positive hepatitis C antibody test result (this test preferable) or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment * NOTE: Subjects with positive hepatitis C antibody due to prior eradicated disease can be enrolled if a confirmatory negative hepatitis C RNA test is obtained
• A known diagnosis of HIV
• Is seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (i.e. subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Subjects who are PCR positive will be excluded. Subjects with hepatitis B surface antibodies and previous hepatitis B vaccination will be eligible
• Has current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. * Note: Stable non-cirrhotic chronic liver disease (including Gilbert’s syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria
• Participant must not have presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant’s safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfill inclusion criteria
• Participant must not have had plasmapheresis within 7 days prior to first dose of study treatment
• Any evidence of active mucosal or internal bleeding
• Participant must not be simultaneously enrolled in any therapeutic clinical trial
• Administration of live or live-attenuated vaccines within 30 days prior to the first dose of study treatment * Exception: Monkeypox vaccine may be given if there are at least 3 days between the vaccine and initiation of study treatment
• Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drug